Real-World Study of Epunamin Combined With DECP Regimen for Adults with Relapsed or Refractory Multiple Myeloma
Led by Shanxi Bethune Hospital · Updated on 2026-03-27
48
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Epunamin combined with a DECP-based regimen for patients with relapsed or refractory multiple myeloma, a type of blood cancer that remains incurable despite current treatments. This observational study aims to assess the effectiveness and safety of this combination in a real-world clinical setting. The study includes adult patients aged 18 to 75 years who have previously received at least one systemic treatment for their condition.
Participants will receive Epunamin along with a DECP-based regimen consisting of Cisplatin, Etoposide, Cyclophosphamide, and Dexamethasone in 28-day cycles. The dosing schedule includes Epunamin administered on specific days, with a step-up dosing approach for some patients, especially those with a high tumor burden or bulky disease. The study plans for patients to receive at least four to six cycles of treatment, with preventive measures for blood clots during therapy.
During the study, researchers will monitor patients regularly to assess treatment responses, including overall response rate after four cycles. They will also evaluate other outcomes such as very good partial response, complete response, minimal residual disease, and time to next treatment. Safety and side effects will be tracked, and statistical methods will be used to analyze survival and treatment effectiveness. Patient enrollment and follow-up will take place from October 2025 to September 2027.
CONDITIONS
Brief Title
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Research Team
T
Tian Weiwei Tian Weiwei, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adults aged 18 to 75 years with relapsed/refractory Multiple Myeloma diagnosed according to revised IMWG criteria
Received at least one prior systemic treatment regimen
Eastern Cooperative Oncology Group Performance Status score of 0-3
Able to understand treatment-related changes and management options during therapy and follow-up, with good treatment adherence and follow-up compliance
Provided written informed consent
You will not qualify if you...
Severe dysfunction of major organs, including cardiac, pulmonary, hepatic, or renal impairment
Unresolved toxicities from prior chemotherapy above grade 1
Peripheral neuropathy grade 2 or higher, or grade 1 with pain
Major surgery, radiotherapy, or severe infection within 14 days before enrollment
High-risk plasma cell leukemia with peripheral blood plasma cells 20% or more
Psychiatric disorders or cognitive impairment affecting compliance
Pregnant or breastfeeding women, or unwillingness to use contraception during the study
Diagnosis or treatment of another malignancy within 2 years before enrollment
Known hypersensitivity to study drugs (Epunamin, Dexamethasone, Cisplatin, Etoposide, Cyclophosphamide)
HIV infection
Participation in another clinical trial within 30 days before enrollment
Any condition deemed unsuitable by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - At least 4 to 6 cycles of 28 days each
Participants receive Epunamin combined with a DECP-based regimen in repeated 28-day cycles. Treatment includes Epunamin, Cisplatin, Etoposide, Cyclophosphamide, and Dexamethasone. Participants achieving clinical benefit will receive at least 4 to 6 cycles of treatment.
Visits occur throughout each 28-day treatment cycle
Follow-up
Duration - Up to study completion in June 2027
Participants are monitored for clinical response and safety after completion of treatment cycles, including assessment of response rates and survival outcomes.
Regular follow-up visits after treatment completion
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Phase I Open-Label Study of SHR-5421 Injection Evaluating Safety and Preliminary Effects in Patients With Multiple Myeloma
Phase I Study of SHR-9539 Injection to Evaluate Safety and Effectiveness in Adults With Multiple Myeloma
Phase 1 Study of TQB2029 Injection to Test Safety and Effects in Adults With Multiple Myeloma
Evaluating Safety and Effectiveness of LVIVO-TaVec200 in Adults with Relapsed or Refractory Multiple Myeloma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.